Day: February 9, 2021

Fourth quarter revenue of $570 million grew 14% quarter-over-quarterExceeded annualized fixed cost reduction target in Q4Positioned for strong organic growth and margin expansion as the recovery takes holdSAN FRANCISCO, Feb. 09, 2021 (GLOBE NEWSWIRE) — Lyft, Inc. (Nasdaq:LYFT) today announced financial results for its fourth quarter and fiscal year ended December 31, 2020.“Despite the difficult backdrop in 2020, we continued to focus on improving our business for the long-term,” said Logan Green, co-founder and chief executive officer of Lyft. “The progress we’ve made has been significant and I believe we are now in a stronger position than at any time in our past. Even as we’ve strengthened our financial position, we’ve continued to fund strategic investments that build on our core competencies and on our marketplace flywheel, to...

Lille, France; Cambridge, MA; February 09, 2021 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced that the positive results from the Phase 2 clinical trial evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC) with incomplete response to ursodeoxycholic acid (UDCA) have been published in the Journal of Hepatology.Dr. Carol Addy, CMO at GENFIT, commented: “These data support the potential for elafibranor as novel treatment in PBC and confirm the rationale of evaluating our compound in this disease in a pivotal Phase 3 trial. PBC remains a disease with significant unmet medical needs, mostly because a substantial number of patients have insufficient response or cannot benefit from existing therapies....

Lille (France), Cambridge (Massachusetts, États-Unis), le 9 février 2021 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique de phase avancée engagée dans l’amélioration de la vie des patients atteints de maladies hépatiques et métaboliques, annonce aujourd’hui la publication dans le Journal of Hepatology des résultats positifs de l’essai clinique de Phase 2 évaluant elafibranor chez des patients atteints de Cholangite Biliaire Primitive (PBC) et présentant une réponse incomplète à l’acide ursodésoxycholique (UDCA).Dr. Carol Addy, Directrice Médicale de GENFIT, a commenté : « Ces données confirment le potentiel d’elafibranor comme nouveau traitement dans la PBC ainsi que le rationnel pour poursuivre son évaluation dans un essai clinique pivot de Phase 3. La PBC demeure une maladie avec de nombreux besoins non-satisfaits, principalement...

UNIONDALE, N.Y., Feb. 09, 2021 (GLOBE NEWSWIRE) — Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced the closing of $117 million in gross proceeds from its previously announced initial public offering and concurrent private placement.The initial public offering of 5,750,000 shares of common stock at a public offering price of $16.00 per share includes the full exercise by the underwriters of their option to purchase an additional 750,000 shares of common stock. Aggregate gross proceeds to Angion were $92.0 million, before deducting underwriting discounts, commissions, and offering expenses. All of the shares in the initial public...

UNIONDALE, N.Y., Feb. 09, 2021 (GLOBE NEWSWIRE) — Arbor Realty Trust, Inc. (NYSE: ABR), today announced that it is scheduled to release fourth quarter 2020 financial results before the market opens on Friday, February 19, 2021. The Company will host a conference call to review the results at 10:00 a.m. Eastern Time on February 19, 2021.A live webcast and replay of the conference call will be available at http://www.arbor.com in the investor relations section of the Company’s website. Those without web access should access the call telephonically at least ten minutes prior to the conference call. The dial-in numbers are (877) 876-9173 for domestic callers and (785) 424-1667 for international callers. Please use participant passcode ABRQ420 when prompted by the operator.A telephonic replay of the call will be available until February...

SAN DIEGO, Feb. 09, 2021 (GLOBE NEWSWIRE) — Genasys Inc. (NASDAQ: GNSS), the global leader in critical communications systems and solutions, today announced financial results for the Company’s fiscal first quarter ended December 31, 2020.Fiscal First Quarter 2021 Financial SummaryFiscal 2021 first quarter revenues were $8.0 million, down from $8.8 million in the prior year quarter due to the delayed shipment of an order because the customer-required payment was not received prior to the quarter end. The payment was subsequently received and the order shipped in early January.Gross profit margin was 46.1%, compared with 52.4% in the first quarter of fiscal 2020. The decrease was attributable to lower revenues, an 86% increase in software engineering personnel over last year and additional engineering charges resulting from...

Revenue Increased 7% Year-Over-YearNon-Prostate Brachytherapy Revenue Increased 92% Year-Over-YearRICHLAND, Wash., Feb. 09, 2021 (GLOBE NEWSWIRE) — Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the second quarter fiscal 2021 ended December 31, 2020.Revenue for the second quarter of fiscal 2021 grew 7% to $2.36 million versus $2.21 million in the prior year comparable period. The company’s core prostate brachytherapy revenue declined 4% versus the second quarter of fiscal 2020 as procedure volumes continued to be impacted by decreased prostate cancer screenings throughout 2020 as a result of COVID-19. Prostate brachytherapy represented 80% of total revenue for the second quarter...

Increases facility by $150 million and extends it to 2026RARITAN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) — Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (“Ortho”), one of the world’s largest pure-play in vitro diagnostics companies, today announced that certain of its subsidiaries successfully amended their June 30, 2014 credit agreement (the “Credit Agreement”) on February 5, 2021.The amendment increases the revolving credit facility under the Credit Agreement by $150 million to an aggregate amount of $500 million and extends the maturity date to February 26, 2026, provided that such date may be accelerated subject to certain circumstances.The Company has filed an 8-K with the Securities and Exchange Commission with more information regarding the Amended Credit Agreement.About Ortho Clinical DiagnosticsOrtho...